These Signs Show Which Stocks Are Having A Hidden Rally, Says Mark Minervini
"You're looking for those really, really great companies, especially if you're going for the bigger move," Minervini said. Continue reading View comments
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| 74.54 | |
| 75.28 | |
| - | |
| 75.28 | |
| 72.9 | |
| 20.94-78.87 | |
| 12 152 M | |
| 163 M | |
| 315 M | |
| -1.06 | |
| 1.16 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
"You're looking for those really, really great companies, especially if you're going for the bigger move," Minervini said. Continue reading View comments
Wall Street expects a year-over-year increase in earnings on higher revenues when Insmed (INSM) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: